Sanodyne
2 known investors
Sanodyne Therapeutics develops SNT-001, an orally administered small-molecule compound intended to treat peripheral neuropathy and neuropathic pain. The drug uses a distinct mechanism of action and is positioned as a potential root-cause therapy for pain.
Investors · 2
Frequently asked questions
- What does Sanodyne do?
- Sanodyne Therapeutics develops SNT-001, an orally administered small-molecule compound intended to treat peripheral neuropathy and neuropathic pain. The drug uses a distinct mechanism of action and is positioned as a potential root-cause therapy for pain.
- Who are Sanodyne's investors?
- Sanodyne's investors include JIC Venture Growth Investments, RDiscovery.